Intro and Overview of Bispecifics in Non-Hodgkin Lymphoma (NHL)

Panelists discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T cell engagement and targeting malignant B cells effectively.

Now Viewing

EP: 1.Intro and Overview of Bispecifics in Non-Hodgkin Lymphoma (NHL)

EP: 2.CD3×CD20 Bispecific Toxicities and Consensus Recommendations for Managing

EP: 3.Community Oncologist Perspective: CD3×CD20 Bispecific Toxicities and Consensus Recommendations

EP: 4.Protocol Development for Administration and AE Management of Bispecifics

EP: 5.Community Oncologist Perspective: Protocol Development for Bispecific Administration and AE Management

EP: 6.Exploring the Management of Cytokine Release Syndrome (CRS)

Video content above is prompted by the following:

Provide a brief overview of the use of bispecifics antibiotics (BsAbs) in NHL

• Please give a brief overview of the four bispecific antibodies cuused in NHL
  • Mosunetuzumab
  • Epicortamab
  • Glofitamab

Recent Videos